Holen Sie sich die Stockscreener-App
261.80
0.33%
0.85
Handel nachbörslich:
261.80
Schlusskurs vom Vortag:
$260.95
Offen:
$260.95
24-Stunden-Volumen:
238.42K
Relative Volume:
0.81
Marktkapitalisierung:
$7.65B
Einnahmen:
$389.13M
Nettoeinkommen (Verlust:
$204.83M
KGV:
38.25
EPS:
6.8443
Netto-Cashflow:
$188.91M
1W Leistung:
+6.02%
1M Leistung:
+3.20%
6M Leistung:
+44.99%
1J Leistung:
+52.83%
1-Tages-Spanne:
$260.53
$266.63
1-Wochen-Bereich:
$242.00
$266.63
52-Wochen-Spanne:
$122.80
$298.30
Krystal Biotech Inc Stock (KRYS) Company Profile
Firmenname
Krystal Biotech Inc
Sektor
Branche
Telefon
(412) 586-5830
Adresse
2100 WHARTON STREET, PITTSBURGH, PA
Compare KRYS vs VRTX, REGN, ARGX, ALNY, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
KRYS
Krystal Biotech Inc
|
261.80 | 7.63B | 389.13M | 204.83M | 188.91M | 6.8443 |
VRTX
Vertex Pharmaceuticals Inc
|
434.30 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
763.04 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
748.25 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
330.34 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
163.81 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Krystal Biotech Inc Stock (KRYS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-27 | Eingeleitet | Wolfe Research | Peer Perform |
| 2026-01-06 | Hochstufung | Citigroup | Neutral → Buy |
| 2025-03-05 | Eingeleitet | Jefferies | Buy |
| 2024-08-06 | Herabstufung | Citigroup | Buy → Neutral |
| 2023-11-20 | Eingeleitet | Goldman | Buy |
| 2023-10-24 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-10-12 | Eingeleitet | Citigroup | Buy |
| 2023-09-07 | Eingeleitet | Berenberg | Buy |
| 2023-04-18 | Eingeleitet | Stifel | Buy |
| 2023-02-28 | Hochstufung | Goldman | Neutral → Buy |
| 2022-08-25 | Herabstufung | Goldman | Buy → Neutral |
| 2022-01-18 | Eingeleitet | BofA Securities | Buy |
| 2021-07-20 | Hochstufung | Goldman | Neutral → Buy |
| 2020-09-18 | Eingeleitet | B. Riley FBR | Buy |
| 2020-06-04 | Eingeleitet | Evercore ISI | Outperform |
| 2019-09-24 | Eingeleitet | Goldman | Neutral |
| 2019-08-06 | Bestätigt | H.C. Wainwright | Buy |
| 2019-06-24 | Bestätigt | Chardan Capital Markets | Buy |
| 2019-06-24 | Bestätigt | H.C. Wainwright | Buy |
| 2019-05-30 | Eingeleitet | Guggenheim | Buy |
| 2018-09-11 | Eingeleitet | Cantor Fitzgerald | Overweight |
Alle ansehen
Krystal Biotech Inc Aktie (KRYS) Neueste Nachrichten
KRYS | Krystal Biotech, Inc. Common Executive Compensation - Quiver Quantitative
Krystal Biotech, Inc. ($KRYS) CEO 2025 Pay Revealed - Quiver Quantitative
KRYS PE Ratio & Valuation, Is KRYS Overvalued - Intellectia AI
Krystal Biotech, Inc. (KRYS) Stock forecasts - Yahoo Finance UK
[DEF 14A] Krystal Biotech, Inc. Definitive Proxy Statement - Stock Titan
SG Americas Securities LLC Purchases 15,591 Shares of Krystal Biotech, Inc. $KRYS - MarketBeat
3 Insider-Owned Growth Companies With Up To 81% Earnings Expansion - simplywall.st
KRYS Forecast, Price Target & Analyst Ratings | KRYSTAL BIOTECH INC (NASDAQ:KRYS) - ChartMill
KRYS News & Events - intellectia.ai
BSP:K1YS34 PB Ratio: 0.20 — 96% Below Median - GuruFocus
Exploring Three High Growth Tech Stocks In The US Market - simplywall.st
(KRYS) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Krystal Biotech stock price forecast: consolidation likely as KRYS hovers near key support and down 2.39% - Traders Union
Assessing Krystal Biotech (KRYS) Valuation After Recent Share Price Weakness - finance.yahoo.com
Krystal Biotech (NASDAQ:KRYS) Coverage Initiated at Wolfe Research - Defense World
Krystal Biotech (BSP:K1YS34) Cyclically Adjusted PB Ratio : (As of Apr. 01, 2026) - gurufocus.com
Krystal Biotech (BSP:K1YS34) EBITDA per Share : R$30.92 (TTM As of Dec. 2025) - GuruFocus
Krystal Biotech (BSP:K1YS34) Gross Property, Plant and Equipment : R$1,033 Mil (As of Dec. 2025) - GuruFocus
Krystal Biotech (BSP:K1YS34) Minority Interest : R$0.00 Mil (As of Dec. 2025) - gurufocus.com
Krystal Biotech Inc Phase 1/2 Clinical Trial of KB103 Final Update Call Transcript - gurufocus.com
Krystal Biotech Inc at TD Cowen Healthcare Conference Transcript - gurufocus.com
Q3 2024 Krystal Biotech Inc Earnings Call Transcript - GuruFocus
Krystal Biotech Inc (BSP:K1YS34) Stock Forecast, Price Targets and Analysts Predictions - GuruFocus
Krystal Biotech (BSP:K1YS34) Shiller PE Ratio : (As of Mar. 28, 2026) - gurufocus.com
BSP:K1YS34 Pretax Margin %: 47.74% — 45% Above Median - GuruFocus
Krystal Biotech (BSP:K1YS34) Unearned Premiums - gurufocus.com
BSP:K1YS34 Graham Number: R$439.15 — 14786% Above Median - GuruFocus
Krystal Biotech Inc (BSP:K1YS34) Dividend - gurufocus.com
Krystal Biotech Inc FDA Approval Call Transcript - GuruFocus
Krystal Biotech (BSP:K1YS34) Cyclically Adjusted PS Ratio : (As of Mar. 28, 2026) - gurufocus.com
Krystal Biotech (BSP:K1YS34) Other Current Payables : R$-0 Mil (As of Dec. 2025) - GuruFocus
Krystal Biotech (BSP:K1YS34) Pre-Tax Income : R$1,047 Mil (TTM As of Dec. 2025) - GuruFocus
Krystal Biotech (BSP:K1YS34) Non Operating Income : R$0 Mil (TTM As of Dec. 2025) - gurufocus.com
BSP:K1YS34 Net Income From Continuing Operations: R$1,124 Mi - GuruFocus
Krystal Biotech Inc KB301 Phase 1 POC Efficacy Data Update Call Transcript - GuruFocus
Krystal Biotech (BSP:K1YS34) Net Income (Discontinued Opera - GuruFocus
Q4 2024 Krystal Biotech Inc Earnings Call Transcript - GuruFocus
Krystal Biotech (BSP:K1YS34) Cyclically Adjusted Price-to-F - gurufocus.com
Krystal Biotech Inc Stock Intrinsic Values | BSP:K1YS34 - gurufocus.com
Krystal Biotech Inc (BSP:K1YS34) Stock Price, Trades & News - gurufocus.com
Q2 2024 Krystal Biotech Inc Earnings Call Transcript - GuruFocus
Krystal Biotech (BSP:K1YS34) Gross-Profit-to-Asset % : 31.50% (As of Dec. 2025) - gurufocus.com
Krystal Biotech Inc (BSP:K1YS34) Stock HoldersInstitutional & Insider Ownership - gurufocus.com
Krystal Biotech Inc (BSP:K1YS34)Valuation Measures & Financial Statistics - GuruFocus
Krystal Biotech (BSP:K1YS34) Fees and Other Income - GuruFocus
Krystal Biotech (BSP:K1YS34) Degree of Operating Leverage : 1.66 (As of Dec. 2025) - GuruFocus
Krystal Biotech (BSP:K1YS34) Degree of Financial Leverage : 2.28 (As of Dec. 2025) - GuruFocus
Krystal Biotech Inc (BSP:K1YS34) Competitors 2026 - gurufocus.com
Krystal Biotech Inc (BSP:K1YS34) Valuation - GuruFocus
Krystal Biotech (BSP:K1YS34) ROE % : 17.59% (As of Dec. 2025) - GuruFocus
Krystal Biotech Inc Stock Historical Valuations - GuruFocus
Finanzdaten der Krystal Biotech Inc-Aktie (KRYS)
Umsatz
Nettogewinn
Free Cashflow
ENV
Krystal Biotech Inc-Aktie (KRYS) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Krishnan Krish S | President and CEO |
Mar 04 '26 |
Sale |
263.17 |
25,000 |
6,579,164 |
1,475,253 |
0.87%
0.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):